Anna Langenbruch

Anna Langenbruch

Auto-generated profile, based on publicly available information

Anna Langenbruch

Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2014 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ALA. Langenbruch
A. Langenbruch
MRM.A. Radtke
M.A. Radtke
MKM. Krensel
M. Krensel
AJA. Jacobi
A. Jacobi
KRK. Reich
K. Reich
MAM. Augustin
M. Augustin

14 November 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MAM. Augustin
M. Augustin
RSR. Sommer
R. Sommer
NKN. Kirsten
N. Kirsten
ADA. Danckworth
A. Danckworth
MRM.A. Radtke
M.A. Radtke
UMU. Mrowietz
U. Mrowietz

5 April 2013 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ALA. Langenbruch
A. Langenbruch
MRM. Radtke
M. Radtke
NFN. Franzke
N. Franzke
JRJ. Ring
J. Ring
RFR. Foelster‐Holst
R. Foelster‐Holst
MAM. Augustin
M. Augustin

20 May 2016 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
ALAnna Langenbruch
Anna Langenbruch
MRMarc Alexander Radtke
Marc Alexander Radtke
AJArnd Jacobi
Arnd Jacobi
SPSandra Purwins
Sandra Purwins
KHKristina Haack
Kristina Haack
MAMatthias Augustin
Matthias Augustin

30 August 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ALA. Langenbruch
A. Langenbruch
MRM.A. Radtke
M.A. Radtke
MGM. Gutknecht
M. Gutknecht
MAM. Augustin
M. Augustin

2 March 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
NMN. Mohr
N. Mohr
MNM. Naatz
M. Naatz
LZL. Zeervi
L. Zeervi
ALA. Langenbruch
A. Langenbruch
TBT. Bieber
T. Bieber
MAM. Augustin
M. Augustin
Background: Progress in the management of atopic dermatitis (AD) and the recent introduction of the first biologic have raised interest in the costs of treating AD.Objectives: Since there is a lack of recent data, the objective of this study was to determine the annual costs of adults with AD from the societal perspective.Methods: A nationwide cross‐sectional study was conducted in 111 dermatological offices under routine conditions. Cost parameters were collected with a standardised questionnaire on disease‐related costs. This questionnaire allows the determination of costs for systemic and topical treatment, outpatient and inpatient visits, rehabilitation stays and travel costs. Direct costs were determined for the statutory health insurance (SHI) and for the patients (out‐of‐pocket costs). Societal costs also included the indirect costs due to incapacity to work. Costs were calculated for all severity grades and further stratified by mild and moderate‐to‐severe AD.Results: From August 2017 to June 2019, N = 1291 adult patients from all over Germany were included. The total annual costs in the group with all severity grades (n = 706) amounted to € 3616 ± € 6452 (median € 874) per patient. For patients with mild AD (n = 367), the annual costs were € 1466 ± € 3029 (median € 551) per patient, while they were € 5229 ± € 7538 (median € 1791) for patients with moderate‐to‐severe AD (n = 682). The total economic burden for treating adult patients with AD in Germany is estimated at more than € 2.2 billion.Conclusions: In total, the data from this study show that compared to for example psoriasis, AD has a moderate level of costs‐of‐illness in Germany. The approval of new therapies is expected to lead to markedly more resource utilisation in the next years.